Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29580661 | 1.00 | MEN1 (0.58) | MEN1KMT2ASIRT6MAPTLMNA | |
| SCHEMBL5832442 | 0.91 | MEN1 (0.57) | MEN1KMT2ASIRT6MAPTLMNA | |
| SCHEMBL1571312 | 0.88 | MEN1 (0.53) | MEN1KMT2ASIRT6MAPTLMNA | |
| SCHEMBL29581035 | 0.87 | MEN1 (0.55) | MEN1KMT2ASIRT6MAPTLMNA | |
| SCHEMBL1042577 | 0.83 | SIRT6 (0.58) | MEN1KMT2ASIRT6MAPTLMNA | |
| SCHEMBL1042578 | 0.83 | SIRT6 (0.58) | MEN1KMT2ASIRT6MAPTLMNA | |
| SCHEMBL22471264 | 0.81 | MEN1 (0.50) | MEN1KMT2ASIRT6MAPTALDH1A1 | |
| SCHEMBL6716676 | 0.81 | MAPT (0.58) | MEN1KMT2ASIRT6MAPTLMNA | |
| SCHEMBL10036155 | 0.80 | SIRT6 (0.63) | MEN1KMT2ASIRT6MAPTLMNA | |
| SCHEMBL25170783 | 0.78 | MAPT (0.54) | MEN1KMT2ASIRT6MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113614087-B | WEE1 inhibitor and preparation and application thereof | 首药控股(北京)股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-20220194960-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | Shouyao Holdings (beijing) Co., Ltd. (CN) | 2022-06-23 | — | — | US | disclosed |
| EP-3943496-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | Shouyao Holdings (Beijing) Co., Ltd. (CN) | 2022-01-26 | — | — | EP | disclosed |
| EP-3943496-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | Shouyao Holdings (Beijing) Co., Ltd. (CN) | 2022-01-26 | — | — | EP | disclosed |
| WO-2020192581-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | 首药控股(北京)有限公司 | 2020-10-01 | — | — | WO | disclosed |
| WO-2020192581-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | 首药控股(北京)有限公司 | 2020-10-01 | — | — | WO | disclosed |
| WO-2009135885-A1 | FUSED PYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS NV (BE) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194960-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | WEE1, WEE2, RCE1 | MEN1 500/4885KMT2A 2209/4885SIRT6 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.